AMG 369 Discriminates Against S1P3 Receptor by 296-Fold

WELLESLEY HILLS, Massachusetts, November 17, 2011 /PRNewswire/ --

S1P1 Lead Compounds will be Offered for Sale at a December 8, 2011 Sealed Bid Sale.  Assets Generated by Epix Pharmaceuticals, Inc. and Amgen

Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that AMG 369 discriminates against S1P3 receptor by 296-fold and that the S1P1 lead compounds, including AMG 369, will be offered December 8, 2011 in a sealed bid sale.  

AMG 369 has 3-nM functional EC50 for hS1P1 receptor and discriminated against S1P3 receptor by 296-fold.  It displayed efficacy in a DTH model with ED70 of 0.2 mpk.  AMG 369 was tested in FIH-enabling toxicology studies.  The therapeutic window is estimated to be at least 40-fold.    

Assets included in the sale include preclinical and toxicology data related to AMG 277, AMG 369 and six backup compounds, existing inventory of these compounds (API), and related patent portfolio.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's office - jffinnjr@finnwarnkegayton.com or +1-781-237-8840; upon receipt of the executed CDA, applicants will receive a bid package, to be completed and returned by December 8, 2011.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts.  He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.  His most recent Assignments for the Benefit of Creditors in the biotech filed include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc. and Source MDx.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at +1-781-237-8840 or jffinnjr@finnwarnkegayton.com